UM
VRTX icon

UniSuper Management’s Vertex Pharmaceuticals VRTX Stock Holding History

UniSuper Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.9M Buy
27,989
+8,331
+42% +$3.69M 0.07% 157
2026
Q1 		$8.78M Sell
19,658
-334
-2% -$156K 0.06% 180
2025
Q4 		$9.06M Sell
19,992
-503
-2% -$217K 0.05% 170
2025
Q3 		$8.03M Buy
20,495
+3,847
+23% +$1.61M 0.05% 193
2025
Q2 		$7.41M Sell
16,648
-189
-1% -$87.1K 0.05% 189
2025
Q1 		$8.16M Buy
16,837
+563
+3% +$262K 0.06% 171
2024
Q4 		$6.55M Buy
16,274
+4,017
+33% +$1.86M 0.05% 189
2024
Q3 		$5.7M Buy
12,257
+200
+2% +$96.1K 0.04% 211
2024
Q2 		$5.65M Buy
12,057
+6,225
+107% +$2.7M 0.05% 197
2024
Q1 		$2.44M Buy
5,832
+3,743
+179% +$1.58M 0.02% 225
2023
Q4 		$850K Sell
2,089
-1,839
-47% -$679K 0.01% 275
2023
Q3 		$1.37M Sell
3,928
-439
-10% -$154K 0.02% 242
2023
Q2 		$1.54M Buy
+4,367
New +$1.47M 0.02% 242

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

UniSuper Management's VRTX Position: Q2 2026 in Review

UniSuper Management increased its Vertex Pharmaceuticals (VRTX) stake by 42% in Q2 2026, buying an estimated $3.69M and bringing the position to 27,989 shares worth $13.9M. The position accounts for 0.07% of the portfolio, ranked #157.

UniSuper Management first reported a position in VRTX in Q2 2023 and has held it in 13 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • UniSuper Management held 27,989 shares of Vertex Pharmaceuticals worth $13.9M as of Q2 2026.
  • UniSuper Management bought 8,331 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3.69M.
  • Vertex Pharmaceuticals made up 0.07% of UniSuper Management's portfolio in Q2 2026, its #157 holding.
  • UniSuper Management first reported a position in Vertex Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on UniSuper Management's 13F filing for Q2 2026, filed 14 Aug 2026.